Healthcare Business Review: Pfizer’s Tofacitinib In Phase II, BioTime’s Published PAPER

Pfizer’s (NYSE:PFE) tofacitinib tablet eased symptoms such as pain and bleeding in patients suffering from ulcerative colitis, which is an inflammatory bowel disease, in a Phase II evaluation. The firm has started three Phase III trials of the medication for ulcerative colitis, which affects some 750,000 Americans, and Pfizer awaits FDA approval for the use of tofacitinib to treat rheumatoid arthritis as well.

Don’t Miss: Medtronic First Quarter Earnings Sneak Peek.

Shares of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) lost almost 30 percent on the day following word that the FDA has placed its IDX184 treatment for hepatitis C on a partial clinical hold, subsequent to a “serious cardiac-related adverse event” that involved a rival drug. The agency wants to further evaluate the safety of IDX184, but Idenix says that during ongoing Phase IIb and previous trials, the drug has shown no evidence of cardiotoxicity.

BioTime, Inc. (AMEX:BTX) and its OncoCyte division have published a paper through which they identify the COL10A1 gene as a potential marker for several types of cancer. The paper’s research is expected to enhance PanC-DxTM, which is a low-cost device that BioTime is developing that will hopefully cancer using blood samples.

DARA BioSciences, Inc. (NASDAQ:DARA) reaches an exclusive distribution arrangement with Seyer Pharmatec for the sale and distribution of Soltamox in the Commonwealth of Puerto Rico. The firm expects to introduce Soltamox later in 2012.

Don’t Miss: Can the Negotiator Resurrect Priceline’s Stock?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More from The Cheat Sheet